{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:01:55Z","timestamp":1772762515303,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T00:00:00Z","timestamp":1237939200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1007\/s00702-009-0200-6","type":"journal-article","created":{"date-parts":[[2009,3,24]],"date-time":"2009-03-24T10:56:25Z","timestamp":1237892185000},"page":"437-441","source":"Crossref","is-referenced-by-count":14,"title":["Experience with long-term treatment with albumin-supplemented botulinum toxin type A"],"prefix":"10.1007","volume":"116","author":[{"given":"Bahram","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Kollewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maresa","family":"Wegener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Bigalke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,25]]},"reference":[{"issue":"Suppl 4","key":"200_CR1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1468-1331.1999.tb00032.x","volume":"6","author":"K Aoki","year":"1999","unstructured":"Aoki K (1999) Preclinical update on Botox (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations. Eur J Neurol 6(Suppl 4):S3\u2013S10","journal-title":"Eur J Neurol"},{"issue":"Suppl 1","key":"200_CR2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1468-1331.2006.01441.x","volume":"13","author":"R Bhidayasiri","year":"2006","unstructured":"Bhidayasiri R, Cardoso F, Truong DD (2006) Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol 13(Suppl 1):21\u201329","journal-title":"Eur J Neurol"},{"issue":"1","key":"200_CR3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1006\/exnr.2000.7583","volume":"168","author":"H Bigalke","year":"2001","unstructured":"Bigalke H, Wohlfarth K, Irmer A, Dengler R (2001) Botulinum A toxin: Dysport improvement of biological availability. Exp Neurol 168(1):162\u2013170","journal-title":"Exp Neurol"},{"key":"200_CR4","doi-asserted-by":"crossref","unstructured":"Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005a) Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev (1):CD004900","DOI":"10.1002\/14651858.CD003633.pub2"},{"key":"200_CR5","doi-asserted-by":"crossref","unstructured":"Costa J, Espirito-Santo C, Borges A, Ferreira JJ, Coelho M, Moore P, Sampaio C (2005b) Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev (1):CD004899","DOI":"10.1002\/14651858.CD004899.pub2"},{"issue":"11","key":"200_CR6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1177\/014107689108401107","volume":"84","author":"DF D\u2019Costa","year":"1991","unstructured":"D\u2019Costa DF, Abbott RJ (1991) Low dose botulinum toxin in spasmodic torticollis. J R Soc Med 84(11):650\u2013651","journal-title":"J R Soc Med"},{"issue":"1","key":"200_CR7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/BF00839203","volume":"239","author":"JS Elston","year":"1992","unstructured":"Elston JS (1992) The management of blepharospasm and hemifacial spasm. J Neurol 239(1):5\u20138","journal-title":"J Neurol"},{"issue":"1","key":"200_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.69.1.121","volume":"69","author":"R Giess","year":"2000","unstructured":"Giess R, Naumann M, Werner E, Riemann R, Beck M, Puls I, Reiners C, Toyka KV (2000) Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 69(1):121\u2013123","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"200_CR9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1006\/exnr.1997.6580","volume":"147","author":"H Goschel","year":"1997","unstructured":"Goschel H, Wohlfarth K, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxin therapy: neutralizing and non-neutralizing antibodies\u2014therapeutic consequences. Exp Neurol 147(1):96\u2013102","journal-title":"Exp Neurol"},{"issue":"2","key":"200_CR10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mds.870090216","volume":"9","author":"P Greene","year":"1994","unstructured":"Greene P, Fahn S, Diamond B (1994) Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 9(2):213\u2013217","journal-title":"Mov Disord"},{"issue":"3","key":"200_CR11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10659","volume":"19","author":"P Haussermann","year":"2004","unstructured":"Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin A. Mov Disord 19(3):303\u2013308","journal-title":"Mov Disord"},{"issue":"10","key":"200_CR12","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/archderm.141.10.1255","volume":"141","author":"M Heckmann","year":"2005","unstructured":"Heckmann M, Plewig G (2005) Low-dose efficacy of botulinum toxin A for axillary hyperhidrosis: a randomized, side-by-side, open-label study. Arch Dermatol 141(10):1255\u20131259","journal-title":"Arch Dermatol"},{"issue":"Suppl 8","key":"200_CR13","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1002\/mds.20024","volume":"19","author":"J Jankovic","year":"2004","unstructured":"Jankovic J (2004) Treatment of cervical dystonia with botulinum toxin. Mov Disord 19(Suppl 8):S109\u2013S115","journal-title":"Mov Disord"},{"issue":"9","key":"200_CR14","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","volume":"45","author":"J Jankovic","year":"1995","unstructured":"Jankovic J, Schwartz K (1995) Response and immunoresistance to botulinum toxin injections. Neurology 45(9):1743\u20131746","journal-title":"Neurology"},{"issue":"7","key":"200_CR15","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1212\/01.WNL.0000055087.96356.BB","volume":"60","author":"J Jankovic","year":"2003","unstructured":"Jankovic J, Vuong KD, Ahsan J (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 60(7):1186\u20131188","journal-title":"Neurology"},{"issue":"6","key":"200_CR16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1136\/jnnp.64.6.751","volume":"64","author":"S Jitpimolmard","year":"1998","unstructured":"Jitpimolmard S, Tiamkao S, Laopaiboon M (1998) Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry 64(6):751\u2013757","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"200_CR17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1331.2006.01448.x","volume":"13","author":"WH Jost","year":"2006","unstructured":"Jost WH (2006) Other indications of botulinum toxin therapy. Eur J Neurol 13(Suppl 1):65\u201369","journal-title":"Eur J Neurol"},{"issue":"4","key":"200_CR18","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s004150050345","volume":"246","author":"KR Kessler","year":"1999","unstructured":"Kessler KR, Skutta M, Benecke R (1999) Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group. J Neurol 246(4):265\u2013274","journal-title":"J Neurol"},{"issue":"4","key":"200_CR19","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1159\/000057902","volume":"47","author":"U Laubis-Herrmann","year":"2002","unstructured":"Laubis-Herrmann U, Fries K, Topka H (2002) Low-dose botulinum toxin-a treatment of cervical dystonia\u2014a double-blind, randomized pilot study. Eur Neurol 47(4):214\u2013221","journal-title":"Eur Neurol"},{"issue":"8","key":"200_CR20","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","volume":"20","author":"A Marchetti","year":"2005","unstructured":"Marchetti A, Magar R, Findley L, Larsen JP, Pirtosek Z, Ruzicka E, Jech R, Slawek J, Ahmed F (2005) Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 20(8):937\u2013944","journal-title":"Mov Disord"},{"issue":"5","key":"200_CR21","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/mds.20376","volume":"20","author":"NI Mejia","year":"2005","unstructured":"Mejia NI, Vuong KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety, and immunogenicity. Mov Disord 20(5):592\u2013597","journal-title":"Mov Disord"},{"issue":"9","key":"200_CR22","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/jnnp.54.9.813","volume":"54","author":"AP Moore","year":"1991","unstructured":"Moore AP, Blumhardt LD (1991) A double blind trial of botulinum toxin \u201cA\u201d in torticollis, with one year follow-up. J Neurol Neurosurg Psychiatry 54(9):813\u2013816","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"200_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/PL00007817","volume":"248","author":"M Naumann","year":"2001","unstructured":"Naumann M (2001) Evidence-based medicine: botulinum toxin in focal hyperhidrosis. J Neurol 248(Suppl 1):31\u201333","journal-title":"J Neurol"},{"issue":"1","key":"200_CR24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, Kunig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64(1):13\u201317","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"200_CR25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000008121","volume":"43","author":"JD Rollnik","year":"2000","unstructured":"Rollnik JD, Matzke M, Wohlfarth K, Dengler R, Bigalke H (2000) Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study. Eur Neurol 43(1):9\u201312","journal-title":"Eur Neurol"},{"issue":"4","key":"200_CR26","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1080\/09638280400009360","volume":"27","author":"A Suputtitada","year":"2005","unstructured":"Suputtitada A, Suwanwela NC (2005) The lowest effective dose of botulinum A toxin in adult patients with upper limb spasticity. Disabil Rehabil 27(4):176\u2013184","journal-title":"Disabil Rehabil"},{"issue":"10","key":"200_CR27","first-page":"1205","volume":"87","author":"A Suputtitada","year":"2004","unstructured":"Suputtitada A, Phanthumchinda K, Locharernkul C, Suwanwela NC (2004) Hemifacial spasm: results of treatment with low dose botulinum toxin injection. J Med Assoc Thai 87(10):1205\u20131211","journal-title":"J Med Assoc Thai"},{"issue":"7","key":"200_CR28","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","volume":"20","author":"D Truong","year":"2005","unstructured":"Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL (2005) Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20(7):783\u2013791","journal-title":"Mov Disord"},{"issue":"7","key":"200_CR29","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880180708","volume":"18","author":"P Bergh Van den","year":"1995","unstructured":"Van den Bergh P, Francart J, Mourin S, Kollmann P, Laterre EC (1995) Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve 18(7):720\u2013729","journal-title":"Muscle Nerve"},{"issue":"6","key":"200_CR30","first-page":"413","volume":"81","author":"A Viriyavejakul","year":"1998","unstructured":"Viriyavejakul A, Vachalathiti R, Poungvarin N (1998) Botulinum treatment for post-stroke spasticity: low dose regime. J Med Assoc Thai 81(6):413\u2013422","journal-title":"J Med Assoc Thai"},{"issue":"3","key":"200_CR31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/PL00004951","volume":"355","author":"K Wohlfarth","year":"1997","unstructured":"Wohlfarth K, Goschel H, Frevert J, Dengler R, Bigalke H (1997) Botulinum A toxins: units versus units. Naunyn Schmiedebergs Arch Pharmacol 355(3):335\u2013340","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"200_CR32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-0404.1992.tb03995.x","volume":"85","author":"YL Yu","year":"1992","unstructured":"Yu YL, Fong KY, Chang CM (1992) Treatment of idiopathic hemifacial spasm with botulinum toxin. Acta Neurol Scand 85(1):55\u201357","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0200-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-009-0200-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-009-0200-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T15:50:02Z","timestamp":1684943402000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-009-0200-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,25]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["200"],"URL":"https:\/\/doi.org\/10.1007\/s00702-009-0200-6","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,25]]}}}